The AAP has updated recommendations for the routine use of seasonal influenza vaccine and antiviral medications for the prevention and treatment of influenza in children.
Details appear in the policy statement, Recommendations for Prevention and Control of Influenza in Children, 2019-2020, which will be published in the October issue of Pediatrics, and have been released early online.
Highlights of these updated recommendations include:
- The A(H1N1)pdm09 and A(H3N2) components of the flu vaccine are new for this season. The B strains are unchanged from last season.
- All pediatric influenza vaccines will be quadrivalent vaccines.
- Both inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) are options for influenza vaccination in children, with no preference of any one product over others.
- New formulations of licensed influenza vaccines with a volume of 0.5 mL per dose have been approved for children 6 through 35 months of age. Children 6 through 35 months of age can therefore receive either the 0.25 mL or the 0.5 mL per dose vaccine formulations available for their age group, with no preference of any one product over others.
- Children 6 months through 8 years of age who are receiving influenza vaccine for the first time this season, or who have received only 1 dose of influenza vaccine before July 1, 2019, need to receive 2 doses of vaccine this season. Children 9 years of age and older only need 1 dose, regardless of previous vaccination history.
- Antiviral medications continue to be recommended for treatment of influenza in children.
This policy statement expands the recommendations in the Influenza chapter in the current edition of Red Book (p 476–490).
Also refer to the Vaccine Status Table and Influenza Resource Page on Red Book Online.
Please also see the recent AAP News article for an overview of these latest recommendations.